{
    "id": 27895,
    "cites": 40,
    "cited_by": 0,
    "reference": [
        "Beigel, J.H. et al. 2020. Remdesivir for the Treatment of Covid-19\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009dPreliminary Report. NEJM. DOI: 10.1056/NEJMoa2007764 Cao, B. et al. 2020. A Trial of Lopinavir\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cRitonavir in Adults Hospitalized with Severe Covid19.",
        "Castagnoli, E. 1984. Some Remarks on Stochastic Dominance. Revista di Matematica per le Scienze Economiche e Sociali 7: 15-28.",
        "Cravens, S.M.R. 2002. The Usage and Meaning of 'Clinical Significance' in Drug-Related Litigation. Washington and Lee Law Review 59: 553-597.",
        "European Medicines Agency (EMA). 2020. ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009dStep 5. Document EMA/CHMP/ICH/436221/2017. Amsterdam: EMA.",
        "Fan, D.S.P. et al. 2003. Ocular-Hypertensive and Anti-Inflammatory Response to Rimexolone Therapy in Children. Archives of Ophthalmology 121: 1716-1721.",
        "Fan, Y. and S. S. Park. 2010. Sharp Bounds on the Distribution of Treatment Effects and Their Statistical Inference. Econometric Theory 26: 931-951.",
        "Ganz, R.A. et al. 2013. Esophageal Sphincter Device for Gastroesophageal Reflux Disease. NEJM 368: 719-727.",
        "Goldman, M. and D.M. Kaplan. 2018. Comparing Distributions by Multiple Testing across Quantiles or CDF Values. Journal of Econometrics 206: 143-166.",
        "Hansen, B. 2020. Introduction to Econometrics (Vol. 1). Web textbook. University of WisconsinMadison, Department of Economics. (https://www.ssc.wisc.edu/~bhansen/probability/, accessed May 21, 2020) (May 2020 version).",
        "Harberger, A.C. 1971. Three Basic Postulates for Applied Welfare Economics: An Interpretive Essay. Journal of Economic Literature 9: 785-797.",
        "Heckman, J.J., J. Smith, and N. Clements. 1997. Making the Most Out of Programme Evaluations and Social Experiments: Accounting for Heterogeneity in Programme Impacts. Review of Economic Studies 64: 487-535.",
        "Hung, I. F.-N. et al. 2020. Triple Combination of Interferon beta-1b, Lopinavir\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cRitonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital with COVID-19: An Openlabel, Randomised, Phase 2 Trial. The Lancet 395: 1695-1704.",
        "Imbens, G.W. and J.M. Wooldridge. 2009. Recent Developments in the Econometrics of Program Evaluation. Journal of Economic Literature 47: 5-86.",
        "Koenker, R. and Y. Bilias. 2001. Quantile Regression for Duration Data: A Reappraisal of the Pennsylvania Reemployment Bonus Experiments. Empirical Economics 26: 199-220.",
        "Lee, M.-J. 2000. Median Treatment Effect in Randomized Trials. JRSS-B 62: 595-604.",
        "Lee, M.-J. and S. Kobayashi. 2001. Proportional Treatment Effects for Count Response Panel Data: Effects of Binary Exercise on Health Care Demands. Health Economics 10: 411428.",
        "Manski, C.F. 1997. Monotone Treatment Response. Econometrica 65: 1311-1334.",
        "Manski, C.F. 2007. Identification for Prediction and Decision. Cambridge: Harvard University Press.",
        "Manski, C.F. 2018a. Credible Ecological Inference for Medical Decisions with Personalized Risk Assessment. Quantitative Economics 9: 541\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c569.",
        "Manski, C.F. 2018b. Reasonable Patient Care under Uncertainty. Health Economics 27: 13971421.",
        "Manski, C.F. 2020a. The Lure of Incredible Certitude. Economics and Philosophy 36: 216-245.",
        "Manski, C.F. 2020b. Bounding the Predictive Values of COVID-19 Antibody Tests. Working Paper (May 14, 2020, version). Department of Economics and Institute for Policy Research, Northwestern University.",
        "Manski, C.F. and F. Molinari. 2020. Estimating the COVID-19 Infection Rate: Anatomy of an Inference Problem. Journal of Econometrics (in press) https://doi.org/10.1016/ j.jeconom.2020.04.041.",
        "Manski, C.F. and A. Tetenov. 2020. Statistical Decision Properties of Imprecise Trials Assessing COVID-19 Drugs NBER Working Paper 27293.",
        "Mullahy, J. 2018a. Individual Results May Vary: Inequality-Probability Bounds for Some Health-Outcome Treatment Effects. Journal of Health Economics 61: 151-162.",
        "Mullahy, J. 2018b. Health Status Measurement. Chapter in Oxford Research Encyclopedia of Economics and Finance, A. Jones, Ed. Oxford: Oxford University Press.",
        "Pocock, S.J. 1992. When to Stop a Clinical Trial. BMJ 305: 235-240.",
        "Rogawski, E.T. et al. 2017. Estimating Differences and Ratios in Median Times to Event. Epidemiology 27: 848-851.",
        "U.S. Dept. of Health and Human Services. 2016. 42 CFR Part 11, Clinical Trials Registration and Results Information Submission; Final Rule. Federal Register 81(183), Part II (September 21, 2016).",
        "U.S. Food and Drug Administration. 2006. Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009dContent and Format: Guidance for Industry. Rockville, MD: U.S. FDA.",
        "U.S. Food and Drug Administration. 2009. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: U.S. FDA.",
        "U.S. Food and Drug Administration, Center for Devices and Radiological Health. 2012.",
        "Transcript of the January 11, 2012, Meeting of the Gastroenterology and Urology Devices Advisory Panel. https://wayback.archive-it.org/7993/20170113191551/ http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Med icalDevices/MedicalDevicesAdvisoryCommittee/Gastroenterology-UrologyDevicesPanel/ UCM291391.pdf (accessed May 28, 2020).",
        "U.S. Food and Drug Administration. 2020a. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda -issues-emergency-use-authorization-potential-covid-19-treatment (May 1, 2020; accessed May 6, 2020).",
        "U.S. Food and Drug Administration. 2020b. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. Rockville, MD: U.S. FDA (version May 14, 2020).",
        "U.S. National Institute on Allergy and Infectious Diseases (NIAID). 2020a. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-acceleratesrecovery -advanced-covid-19 (April 29, 2020; accessed May 6, 2020).",
        "U.S. National Institute on Allergy and Infectious Diseases (NIAID). 2020b. Adaptive COVID-19 Treatment Trial (ACTT). ClinicalTrials.gov Identifier: NCT04280705.",
        "Washington Post. 2020. Gilead\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s remdesivir improves recovery time of coronavirus patients in NIH trial. https://www.washingtonpost.com/business/2020/04/29/gilead-says-positiveresults -coronavirus-drug-remdesivir-will-be-released-by-nih/ (reported April 29, 2020; accessed May 6, 2020).",
        "Zarin, D.A. et al. 2011. The ClinicalTrials.gov Results Database\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009dUpdate and Key Issues. NEJM 364: 852-860.",
        "Zarin, D.A. et al. 2016. Trial Reporting in ClinicalTrials.gov\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009dThe Final Rule. NEJM 375: 1998-2004."
    ]
}